Dashboard
Manage Tickers

IMABI-Mab

Nasdaq i-mabbiopharma.com


$ 1.11 $ -0.09 (-7.14 %)    

Tuesday, 03-Sep-2024 12:32:33 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 465.25 $ -8.43 (-1.78 %)
DIA $ 411.49 $ -2.70 (-0.65 %)
SPY $ 555.04 $ -5.79 (-1.03 %)
TLT $ 97.50 $ 0.45 (0.46 %)
GLD $ 229.65 $ -0.65 (-0.28 %)
$ 1.13
$ 1.19
$ 1.12 x 600
$ 1.50 x 400
$ 1.11 - $ 1.19
$ 0.99 - $ 2.54
206,092
na
9.12M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-i-mab-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on I-MA...
08/29/2024 11:54:23

HC Wainwright & Co. analyst Andrew Fein reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $8 price target.

i-mabs-cash-and-cash-equivalents-and-short-term-investments-as-of-june-30-2024-of-2075m-with-cash-runway-expected-into-2027
I-Mab's Cash And Cash Equivalents, And Sho...
08/28/2024 11:31:28

i-mab-q2-2024-adjusted-epads-007-up-from-028-yoy
I-MAB Q2 2024 Adjusted EPADS $(0.07) Up Fr...
08/28/2024 11:30:07

i-mab-h1-2024-adjusted-epads-028-up-from-105-yoy
I-MAB H1 2024 Adjusted EPADS $(0.28) Up Fr...
08/28/2024 11:29:29

i-mab-appointed-wei-fu-as-new-chair-as-dr-pamela-m-klein-stepped-down-from-interim-role-named-dr-sean-xi-yong-fu-as-interim-ceo-effective-july-15-taking-over-from-raj-kannan
I-Mab Appointed Wei Fu As New Chair As Dr....
07/15/2024 11:36:54

I-Mab (NASDAQ:IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the ...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
06/05/2024 12:06:43

Core News & Articles
I-Mab Enters Clinical Collaboration With B...
06/05/2024 11:02:19

The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody join...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
06/04/2024 16:31:07

imab---analyzing-i-mabs-short-interest
(IMAB) - Analyzing I-MAB's Short Interest
05/07/2024 18:45:25

needham-reiterates-buy-on-i-mab-maintains-6-price-target
Needham Reiterates Buy on I-MAB, Maintains...
04/12/2024 10:04:44

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $6 price target.

nvidia-to-rally-around-20-here-are-10-top-analyst-forecasts-for-monday
NVIDIA To Rally Around 20%? Here Are 10 To...
03/18/2024 11:52:31

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

piper-sandler-maintains-overweight-on-i-mab-lowers-price-target-to-10
Piper Sandler Maintains Overweight on I-MA...
03/18/2024 11:16:57

Piper Sandler analyst Joseph Catanzaro maintains I-MAB (NASDAQ:IMAB) with a Overweight and lowers the price target from $15 ...

hc-wainwright--co-reiterates-buy-on-i-mab-lowers-price-target-to-8
HC Wainwright & Co. Reiterates Buy on I-MA...
03/18/2024 10:41:42

HC Wainwright & Co. analyst Andrew Fein reiterates I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $18 t...

needham-maintains-buy-on-i-mab-lowers-price-target-to-6
Needham Maintains Buy on I-MAB, Lowers Pri...
03/15/2024 13:28:40

Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $8 to $6.

i-mab-fy23-eps-076-vs-163-yoy-revenue-39m-vs-321m-yoy-fy23-epads-176-vs-375-yoy
I-Mab FY23 EPS $(0.76) Vs $(1.63) YoY; Rev...
03/14/2024 21:03:44

Non-GAAP Net LossNon-GAAP adjusted net loss, which excludes share-based compensation expenses and impairment of goodwill, for t...

needham-maintains-buy-on-i-mab-lowers-price-target-to-8
Needham Maintains Buy on I-MAB, Lowers Pri...
02/08/2024 20:12:16

Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $23 to $8.

looking-into-i-mabs-recent-short-interest
Looking Into I-MAB's Recent Short Interest
02/07/2024 18:30:30

i-mab-inks-deal-to-divest-its-assets-and-business-operations-in-china
I-Mab Inks Deal To Divest Its Assets And B...
02/07/2024 11:40:14

The Company will transfer 100% of the outstanding equity interest in I-Mab Biopharma Co., Ltd., a wholly owned subsidiary of th...

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
12/15/2023 21:31:40

t-investment-reports-989-stake-in-i-mab
T Investment Reports 9.89% Stake In I-MAB
12/01/2023 19:46:17

-SEC Filing

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION